The portfolio maintains a sizable cost advantage over competitors, priced within the least expensive fee quintile among peers.
KraneShares MSCI All China Hlth Care ETF KURE
Morningstar’s Analysis KURE
Will KURE outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 41.3
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A | 8.07 | 3.6 Mil | Healthcare |
Jiangsu Hengrui Pharmaceuticals Co Ltd Class A | 6.82 | 3.1 Mil | Healthcare |
BeiGene Ltd Ordinary Shares | 4.17 | 1.9 Mil | Healthcare |
CSPC Pharmaceutical Group Ltd | 3.91 | 1.8 Mil | Healthcare |
WuXi Biologics (Cayman) Inc | 3.85 | 1.7 Mil | Healthcare |
Zhangzhou Pientzehuang Pharmaceutical Co Ltd Class A | 3.35 | 1.5 Mil | Healthcare |
Innovent Biologics Inc | 3.14 | 1.4 Mil | Healthcare |
Aier Eye Hospital Group Co Ltd Class A | 2.85 | 1.3 Mil | Healthcare |
Wuxi AppTec Co Ltd Class A | 2.70 | 1.2 Mil | Healthcare |
Chongqing Zhifei Biological Products Co Ltd Class A | 2.47 | 1.1 Mil | Healthcare |